Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan

Reuters

Oct 01

Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan

Sysmex Corporation has announced the signing of an exclusive agreement with QIAGEN N.V. for the distribution and supply of clinical diagnostic products related to infectious diseases and oncology in Japan. The agreement builds on a partnership between the two companies that has spanned more than ten years. Under the new strategic alliance, Sysmex will distribute QIAGEN's clinical diagnostic instruments and reagents, including leading products such as the QuantiFERON-TB Gold Plus test for tuberculosis and cancer molecular diagnostics. The companies also plan to explore joint research and development initiatives and may expand the range of products available in the Japanese market. This collaboration aims to enhance the delivery of clinical testing solutions and contribute to advancements in healthcare.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sysmex Corporation published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2572783585"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572783585\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572783585?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 14:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572783585","market":"nz","top_or_hot":-1,"title":"Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sysmex Corporation has announced the signing of an exclusive agreement with QIAGEN N.V. for the distribution and supply of clinical diagnostic products related to infectious diseases and oncology in Japan. The agreement builds on a partnership between the two companies that has spanned more than ten years. Under the new strategic alliance, Sysmex will distribute QIAGEN's clinical diagnostic instruments and reagents, including leading products such as the QuantiFERON-TB Gold Plus test for tuberculosis and cancer molecular diagnostics. The companies also plan to explore joint research and development initiatives and may expand the range of products available in the Japanese market. This collaboration aims to enhance the delivery of clinical testing solutions and contribute to advancements in healthcare.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sysmex Corporation published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-01 14:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sysmex Corporation has announced the signing of an exclusive agreement with QIAGEN N.V. for the distribution and supply of clinical diagnostic products related to infectious diseases and oncology in Japan. The agreement builds on a partnership between the two companies that has spanned more than ten years. Under the new strategic alliance, Sysmex will distribute QIAGEN's clinical diagnostic instruments and reagents, including leading products such as the QuantiFERON-TB Gold Plus test for tuberculosis and cancer molecular diagnostics. The companies also plan to explore joint research and development initiatives and may expand the range of products available in the Japanese market. This collaboration aims to enhance the delivery of clinical testing solutions and contribute to advancements in healthcare.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sysmex Corporation published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL4DHLYj:1","article_id":"2572783585","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572783585","pubTimestamp":1759300543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sysmex Corporation has announced the signing of an exclusive agreement with QIAGEN N.V. for the distribution and supply of clinical diagnostic products related to infectious diseases and oncology in Japan. The agreement builds on a partnership between the two companies that has spanned more than ten years. Under the new strategic alliance, Sysmex will distribute QIAGEN's clinical diagnostic instruments and reagents, including leading products such as the QuantiFERON-TB Gold Plus test for tuberculosis and cancer molecular diagnostics. The companies also plan to explore joint research and development initiatives and may expand the range of products available in the Japanese market. This collaboration aims to enhance the delivery of clinical testing solutions and contribute to advancements in healthcare.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","QGEN":"快而精医药","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD"},"translate_title":"Sysmex与QIAGEN签署日本传染病和肿瘤诊断独家经销协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9},"content_text":"Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan\n    \n\n        Sysmex Corporation has announced the signing of an exclusive agreement with QIAGEN N.V. for the distribution and supply of clinical diagnostic products related to infectious diseases and oncology in Japan. The agreement builds on a partnership between the two companies that has spanned more than ten years. Under the new strategic alliance, Sysmex will distribute QIAGEN's clinical diagnostic instruments and reagents, including leading products such as the QuantiFERON-TB Gold Plus test for tuberculosis and cancer molecular diagnostics. The companies also plan to explore joint research and development initiatives and may expand the range of products available in the Japanese market. This collaboration aims to enhance the delivery of clinical testing solutions and contribute to advancements in healthcare.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sysmex Corporation published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}